Add Formweb to your mobile device
Search results for:
filgrastim
filgrastim
Brand names: Granix (tbo-filgrastim), Neupogen, Nivestym, Releuko, Zarxio
| Form | Strength | ANAN | ASMP | LACH | LALK | LOHH | LOLR | LOWC | SDSD | SESE | SFSF | Formulary Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SOLUTION, SUBCUTANEOUS | 300 mcg/0.5 mL; 300 mcg/mL; 480 mcg/0.8 mL; 480 mcg/1.6 mL; aafi 300 mcg/0.5 mL; aafi 480 mcg/0.8 mL; ayow 300 mcg/0.5 mL; ayow 480 mcg/0.8 mL; sndz 300 mcg/0.5 mL; sndz 480 mcg/0.8 mL |
Last updated: May. 1, 2024
- Therapeutic Interchange: Biosimilar and Reference Products Conversion List for Adults
- Do Not Tube-LALK
- Do Not Tube-LACH
- Restricted: filgrastim (Neupogen) is restricted to pediatric patients requiring doses less than 180mcg
Medications Approved for Automatic Therapeutic Interchange Dosage Conversion Guidelines
(Note: “Therapeutic Interchange” should be placed in the order comments)
Exceptions: Pediatric patients needing doses <180mcg should receive Neupogen for accurate dosing. (Zarxio is unable to measure doses <180mcg)
Granulocyte Colony Stimulating Factors (G-CSF)
Medication
Brand Name
Available Dosage
Frequency
Formulary Medication
Equivalent Dose
Frequency
Filgrastim
Neupogen
300 mcg
480 mcg
Daily
Tbo-fligrastim
(Granix)
Same dose as ordered
Daily
Biosimilar and Reference Products Interchange List for Adults
Medication
Reference Drug or Biosimilar
Formulary Status
Automatic Therapeutic Interchange
Inpatient1
Outpatient
Granix (tbo-filgrastim)
Biologic (US); biosimilar in Europe
Formulary
(preferred)
Use Granix
Use Granix unless third party payer requires other filgrastim product
Zarxio (filgrastim-sndz)
Nivestym (filgrastim-aafi) Releuko (filgrastim-ayow)
Biosimilars
Formulary, restricted to OP
(not preferred)
Interchange to Granix
Interchange to Granix unless third party payer requires other filgrastim product
Neupogen (filgrastim)
Reference
Neupogen is the only filgrastim product with approval for hematopoietic radiation injury syndrome.